Abstract
Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 83-91 |
| Number of pages | 9 |
| Journal | Angiogenesis |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2003 |
Bibliographical note
Funding Information:This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis inhibition
- Angiostatic peptides
- Angiostatic proteins
- Designer peptides and review
Fingerprint
Dive into the research topics of 'Discovery and development of anti-angiogenic peptides: A structural link'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS